Related Experiment Video
Updated: May 5, 2026
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.1K
Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study
Alicia Trenas-Calero1, Nuria Prieto-Laín1, Ana I Gómez-Hernández1
1Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, 29010 Málaga, Spain.
Pharmaceuticals (Basel, Switzerland)
|May 4, 2026
Summary
Once-weekly semaglutide significantly reduced heart failure and kidney disease events in patients with cardiovascular-kidney-metabolic syndrome. This treatment also improved heart failure status, glycemic control, and body weight.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Limited evidence exists on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in cardiovascular-kidney-metabolic (CKM) syndrome.
- CKM syndrome involves complex interactions between cardiovascular disease, chronic kidney disease, and metabolic dysfunction.
Purpose of the Study:
- To analyze the efficacy and safety of once-weekly semaglutide in patients with CKM syndrome.
- To evaluate semaglutide's impact on heart failure and kidney disease events.
Main Methods:
- Observational, real-world study comparing semaglutide-treated patients (Sema-CKM Group) with a control group (Control-CKM Group).
- Propensity score matching (1:1) was used to create comparable groups.
- Primary outcomes assessed were heart failure events and major kidney disease events at 24 months.
Main Results:
- Semaglutide significantly reduced heart failure events (20.9% vs. 40.1%) and major kidney disease events (36 vs. 65) compared to controls.
- Patients on semaglutide showed improved heart failure health status (OR: 2.80) and better glycemic control (HbA1c -0.7%).
- Semaglutide treatment also led to significant body weight reduction (-9.3 kg).
Conclusions:
- Once-weekly semaglutide demonstrates efficacy in reducing cardiovascular and kidney events in patients with CKM syndrome.
- Semaglutide offers benefits for heart failure status, metabolic control, and weight management in this population.
- Further research into GLP-1 RAs for CKM syndrome is warranted.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
01:26Nephrotic Syndrome II : Assessment and Medical Management
409
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
409
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
01:21Drug Dosing: Obese Patients
368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423